Ranibizumab and Reduced Fluence PDT for AMD

NCT00527475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: ranibizumab
DRUG: verteporfin

Sponsor

Texas Retina Associates

Collaborators

[object Object]